PYC Therapeutics Limited (PYC) AI Stock Analysis

• Market Cap: AU$699.91M
• Dividend Yield: N/A
• Average Volume (3M): 855.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: N/A
• EPS Growth: -84.82%
• Country: AU
• Employees: 23
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 583,260,440
• 10 Day Avg. Volume: 499,431
• 30 Day Avg. Volume: 855,225
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.35
• Price Target Upside: 89.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 51 Neutral
• Price Target: AU$1.50 ▲(20.97% Upside)

The overall score for PYC Therapeutics is driven by solid financial stability due to a strong balance sheet, despite ongoing profitability and cash flow challenges. Technical indicators suggest a mixed momentum outlook, while valuation remains weak due to lack of profitability and dividend yield.

Positive Factors

Clinical Trials

PYC-003 is now being assessed in a Phase I in healthy volunteers, entering a catalyst-rich period across all of its clinical programs.

Market Potential

NVS Acquisition of RGLS Further Validates MOA for Potentially Best-in-Class PYC-003.

Valuation

The upfront payment of US$7.00 per share infers an EV of US$0.8B – if applied to PYC’s capital structure, this generates a PYC valuation of AU$2.35 per share (US$1.50).

Negative Factors

Risk Assessment

Bloom Burton is initiating research coverage of genetic medicine company, PYC Therapeutics, with a BUY rating (Speculative risk).

Valuation Uncertainty

Applying a 15% probability to the CVR, increases the valuation to AU$2.70 (US$1.72).

PYC Therapeutics Limited Business Overview & Revenue Model

Company Description

PYC Therapeutics Limited (PYC) is a biotechnology company focused on the development of innovative therapies for the treatment of genetic diseases. The company operates in the biopharmaceutical sector, leveraging its proprietary drug delivery platforms to create precision medicines. PYC's core products include RNA-based therapeutics designed to target and correct genetic mutations at their source, offering potential treatments for a range of inherited disorders.

How the Company Makes Money

PYC Therapeutics Limited generates revenue primarily through the development and commercialization of its proprietary RNA-based therapeutic candidates. The company's revenue streams may include upfront payments, milestone payments, and royalties from partnerships or licensing agreements with larger pharmaceutical companies. These collaborations enable PYC to leverage the resources and expertise of established firms to advance its drug candidates through the clinical trial process and eventually to market. Additionally, PYC may receive research and development grants or funding from governmental or private entities to support its ongoing projects. The company's ability to secure strategic partnerships and successfully bring its therapies to market are significant factors contributing to its earnings.

PYC Therapeutics Limited Financial Statement Overview

Summary

PYC Therapeutics shows strong revenue growth, but faces ongoing profitability and cash flow challenges, with negative free cash flow and net losses. The balance sheet is strong with minimal debt, offering financial stability, yet operational efficiency improvements are needed.

Income Statement

PYC Therapeutics has shown a significant increase in revenue over the recent years, with a revenue growth rate of 39.58% from 2023 to 2024. However, the company continues to operate at a loss, with negative net profit and EBIT margins indicating ongoing profitability challenges. The consistent operating losses highlight the need for cost management and operational efficiency improvements.

Balance Sheet

The company's balance sheet shows a solid equity base with an equity ratio of 88.23%, suggesting low leverage and financial stability. However, the debt-to-equity ratio is low at 0.01, indicating conservative use of debt, which might limit growth funding options. The return on equity remains negative due to net losses, impacting investor returns.

Cash Flow

PYC Therapeutics has a concerning trend of negative free cash flow, worsening from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting challenges in generating cash from operations. Despite significant financing cash inflows, the reliance on external funding raises sustainability concerns.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	22.06M	15.81M	16.04M	3.07M	2.40M
Gross Profit	22.06M	14.92M	15.20M	2.45M	1.85M
EBITDA	-38.12M	-38.25M	-29.39M	-21.04M	-8.89M
Net Income	-37.73M	-22.79M	-13.86M	-17.77M	-6.82M
Balance Sheet
Total Assets	91.24M	37.17M	45.35M	57.94M	31.55M
Cash, Cash Equivalents and Short-Term Investments	66.87M	15.57M	29.11M	51.50M	25.43M
Total Debt	1.11M	315.49K	943.77K	730.35K	798.14K
Total Liabilities	10.18M	8.72M	5.15M	4.02M	1.35M
Stockholders Equity	80.50M	27.75M	39.35M	53.04M	28.45M
Cash Flow
Free Cash Flow	-38.90M	-24.91M	-22.17M	-12.38M	-5.85M
Operating Cash Flow	-38.59M	-24.42M	-21.78M	-11.79M	-5.75M
Investing Cash Flow	-307.04K	-477.12K	32.68M	-15.52M	-13.77M
Financing Cash Flow	90.19M	11.44M	-182.36K	38.56M	25.11M

PYC Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.24
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PYC, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 1.31, below the 50-day MA of 1.27, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.04 is Neutral, neither overbought nor oversold. The STOCH value of 45.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PYC.

PYC Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CUV	74 Outperform	$615.52M	15.86	19.93%	0.41%	12.74%	27.56%
CU6	53 Neutral	AU$1.71B	―	-53.99%	―	―	-40.19%
BOT	53 Neutral	AU$294.17M	―	-56.99%	―	10.76%	-195.89%
Sector *	51 Neutral	$7.39B	0.36	-62.86%	2.36%	15.48%	-2.68%
PYC	51 Neutral	AU$699.91M	―	-112.97%	―	―	-84.82%
IMM	50 Neutral	$388.98M	―	-31.16%	―	―	14.47%
OPT	30 Underperform	AU$738.77M	―		―	-24.46%	-7.90%

PYC Therapeutics Limited Corporate Events

PYC Therapeutics Updates Investors in Q3 Webinar

PYC Therapeutics Limited held a Q3 investor webinar to provide updates on its business activities. The presentation emphasized the reliance on publicly available information and included cautionary notes about forward-looking statements, highlighting potential risks and uncertainties that could impact future outcomes.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$3.90 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics to Host Investor Webinar on Q3 Progress

PYC Therapeutics Limited has announced an investor webinar scheduled for August 1, 2025, to update shareholders on its Q3 2025 progress. The company is advancing several drug development programs, including treatments for Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, Autosomal Dominant Polycystic Kidney Disease, and Phelan McDermid Syndrome, with various clinical trials underway and significant milestones anticipated in 2025 and 2026. This progress underscores PYC’s commitment to addressing genetic diseases and could enhance its position in the biotechnology industry.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Advances Drug Development Pipeline in Q2 2025

PYC Therapeutics has made significant progress in its drug development programs during Q2 2025, including advancing clinical trials for treatments targeting polycystic kidney disease, retinitis pigmentosa type 11, and autosomal dominant optic atrophy. The company also presented pre-clinical data for a neurodevelopmental disorder treatment. Following a successful capital raise, PYC is well-positioned financially to continue its journey toward becoming a commercial-stage company, with key milestones expected in the latter half of 2025.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Advances Clinical Trials for PKD Treatment

PYC Therapeutics has announced the progression of its clinical trials for PYC-003, a drug candidate targeting Polycystic Kidney Disease (PKD). Following approval from the Safety Review Committee, the company will advance to Part B of the Single Ascending Dose study and escalate dosing in Part A. This milestone allows PYC to commence patient dosing and aligns with their timeline to initiate repeat dose studies by Q4 2025, marking significant progress in their efforts to address PKD.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Advances Phelan-McDermid Syndrome Program

PYC Therapeutics announced progress in its Phelan-McDermid Syndrome (PMS) program, presenting data at the PMS Global Congress in Barcelona. The data shows that their drug candidate, PYC-002, restores missing gene expression and rescues functional deficits in neurons, addressing the underlying cause of PMS. This advancement is significant as there are currently no approved treatments for PMS, and the program is expected to enter clinical trials in about 12 months, marking the company’s fourth first-in-class drug candidate with disease-modifying potential.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Advances VP-001 with FDA Trial Design Approval

PYC Therapeutics has received FDA alignment on the design of its registrational trial for VP-001, a drug candidate aimed at treating Retinitis Pigmentosa type 11 (RP11), a blinding eye disease. The FDA’s acceptance of PYC’s trial design, including the use of a sham control arm and specific inclusion criteria, marks a significant step towards a New Drug Application. This progress could enhance PYC’s positioning in the biotechnology industry by advancing its clinical pipeline and potentially offering a new treatment option for RP11 patients.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Advances ADOA Clinical Trial with Dose Escalation Approval

PYC Therapeutics has received approval from the Safety Review Committee to escalate the dose of its investigational drug candidate, PYC-001, in its clinical trial for Autosomal Dominant Optic Atrophy (ADOA). This approval allows the company to move from cohort 2 to cohort 3, increasing the dose from 10 to 30 micrograms per eye. The progression of this trial is a significant step towards establishing the safety and efficacy of PYC-001, with plans for further studies and a potential Phase 2/3 trial to support a New Drug Application.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Updates Investors in Q2 Webinar

PYC Therapeutics Limited recently held a Q2 investor webinar to update stakeholders on its business activities. The presentation emphasized the company’s ongoing commitment to advancing its scientific endeavors, though it cautioned that the information provided should be considered in conjunction with past and future announcements. The company highlighted the inherent risks and uncertainties in its forward-looking statements, urging stakeholders to exercise caution when interpreting the information.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Advances Clinical Trial for PKD Treatment

PYC Therapeutics Limited has received approval to escalate dosing in its clinical trial for PYC-003, a drug candidate for Polycystic Kidney Disease (PKD). The Safety Review Committee has approved the increase in dosage for the second cohort of healthy volunteers, with plans to initiate dosing in PKD patients upon successful review of safety data. This progression marks a significant step in PYC’s clinical trial process, potentially leading to a Phase 2/3 trial aimed at supporting a New Drug Application for PYC-003.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Announces Cessation of Securities

PYC Therapeutics Limited announced the cessation of certain securities due to unmet conditions, affecting options expiring in 2026, 2027, and 2028. This announcement may impact the company’s capital structure and investor relations, as it reflects on the company’s strategic decisions regarding its financial instruments.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

PYC Therapeutics Announces Investor Webinar and Updates on Drug Development Progress

PYC Therapeutics Limited has announced an investor webinar scheduled for May 30, 2025, to update shareholders on its progress in Q2 2025. The company is advancing several drug development programs, including treatments for Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, Autosomal Dominant Polycystic Kidney Disease, and Phelan McDermid Syndrome. These programs are at various stages of clinical trials, with significant milestones anticipated in 2025 and 2026, potentially impacting the company’s market position and stakeholder interests.

The most recent analyst rating on (AU:PYC) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.